ClinicalTrials.gg
CompletedNCT00562549Updated Apr 30, 2026

Safety and Effects of SLx-2101 Taken for up to 14 Days on Blood Pressure in Patients With Hypertension

A Phase 2 interventional study of SLx-2101 in Hypertension, sponsored by Retension Pharmaceuticals. Inc.. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by Retension Pharmaceuticals. Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 223 studies in Hypertension with a site in United Kingdom — 35 open to participants now, 43 under way, 7 of them phase 3. Hypertension · United Kingdom.

Enrollment
150th of 172
26 · median 125
Started
2007
with 4 others
Phase 2
26 of 223
none open now
Registered
33rd of 223
by date

Among the 223 studies in Hypertension with a site in United Kingdom, this one is the 150th largest by enrollment of the 172 interventional ones that give a count, is one of 5 that started in 2007, is one of 26 in phase 2, and was the 33rd registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

35 of the 223 studies in Hypertension with a site in United Kingdom are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 223 studies in Hypertension with a site in United Kingdom, or all of them as a file.
02

Study summary

The purpose is to determine the effective dosage and to study the effects of this dosage taken for 12 days on systolic and diastolic blood pressure in patients with hypertension.

Read the detailed description
  1. Office seated peripheral systolic and diastolic blood pressure
  2. Adverse events and vital signs
  3. Plasma concentrations of SLx-2101
03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or females between 18 and 80 years, inclusive
  • Moderate to severe hypertension
  • Body weight within a range of 18 - 32 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Subject is receiving more than four antihypertensive agents
  • History of drug abuse
  • Exposure to a new chemical entity within 3 months prior to the first day of dosing
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    1

    SLx-2101

    Drug: SLx-2101

  • Placebo comparator
    2

    Matching Placebo Dose

    Drug: SLx-2101

Interventions

06

What researchers measure

Primary outcomes

  1. Office seated peripheral systolic and diastolic blood pressure

    Time frame: 12 days

Secondary outcomes

  1. Adverse events and changes in vital signs

    Time frame: 12 days

07

Study locations

1 site
  • Addenbrooke's Hospital
    Cambridge, CB2 2QQ, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2007, a primary completion of Dec 2007 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2007
First posted
Nov 22, 2007
Start
Jul 2007
Primary completionActual
Dec 2007
CompletionActual
Dec 2007
Last update
Apr 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00562549
Lead sponsor
Retension Pharmaceuticals. Inc.
Responsible party
Sponsor
First posted
Nov 22, 2007
Start date
Jul 2007
Primary completion
Dec 2007
Completion
Dec 2007
Last update
Apr 30, 2026

Study contacts

Ian B Wilkinson, MD
principal investigator · Addenbrooke's Hospital, Cambridge

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SLX-2101

Start the discussion